<DOC>
	<DOCNO>NCT00000724</DOCNO>
	<brief_summary>To study safety effectiveness trimetrexate ( TMTX ) plus leucovorin calcium rescue ( LCV ) treatment Pneumocystis carinii pneumonia ( PCP ) patient AIDS , patient HIV positive , laboratory confirmation HIV infection yet establish high risk HIV infection , respond standard treatment demonstrate severe life-threatening intolerance conventional therapy PCP . The drug trimethoprim / sulfamethoxazole ( TMP / SMX ) pentamidine , usually use treat PCP AIDS patient , proven ineffective many patient discontinue many patient severe side effect . TMTX choose trial find active PCP organism laboratory test , preliminary trial combination LCV , high response rate without severe toxicity .</brief_summary>
	<brief_title>A Study Trimetrexate With Leucovorin Rescue AIDS Patients Who Are Refractory Standard Therapies Pneumocystis Carinii Pneumonia</brief_title>
	<detailed_description>The drug trimethoprim / sulfamethoxazole ( TMP / SMX ) pentamidine , usually use treat PCP AIDS patient , proven ineffective many patient discontinue many patient severe side effect . TMTX choose trial find active PCP organism laboratory test , preliminary trial combination LCV , high response rate without severe toxicity . AMENDED : 08/01/90 . As August 31 , 1989 , 437 patient enrol uncontrolled study trimetrexate PCP : 214 TX 301/ACTG 039 ( trimetrexate patient intolerant approved therapy ) 223 NS 401 ( trimetrexate patient refractory approved therapy ) . The analysis overall response rate , stringently define receive least 14 day trimetrexate alive follow-up 1 month completion therapy , reveal 84/159 intolerant patient 48/160 refractory patient respond , rate 53 percent 30 percent , respectively . These response rate include individual receive least one dose trimetrexate . Of 111 patient ventilator-dependent study entry , 18 complete course therapy alive month later , response rate 16 percent . All ventilate patient die . The common severe ( grade 3 4 ) toxicity : transaminase elevation ( &gt; 5 x normal ) 94 patient , anemia ( &lt; 7.9 g/dl ) 109 , neutropenia ( &lt; 750 cells/mm3 ) 58 , fever ( &gt; 40 C ) 37 , thrombocytopenia ( &lt; 50000 platelets/mm3 ) 27 . Toxicity require discontinuation therapy approximately 5 percent patient . Original design : Patients enter study give TMTX day 21 day LCV 4 time day ( every 6 hour ) 24 day . Doses determine body size . Both drug give intravenous infusion , LCV may give orally first 10 day . Doses adjust side effect , low white blood cell count , severe . During 21-day trial , zidovudine ( AZT ) may use , possible increase bone marrow toxicity . AZT may resume soon administration TMTX LCV complete . After treatment TMTX , patient may treat drug prevent recurrence PCP discretion his/her physician .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Trimetrexate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antihypertensive agent . Concurrent Treatment : Allowed : Blood product . Ventilatory support . Prior Medication : Required : At least 7 day trimethoprim / sulfamethoxazole parenteral pentamidine . Allowed : Myelosuppressive nephrotoxic agent include zidovudine , must discontinue trial . No improvement ventilatory status , define change decrease arterial alveolar difference ( ( Aa ) DO2 ) 72 hour prior entry . ( Aa ) DO2 determine room air , receive FiO2 100 percent 10 minute via tightly fit nonrebreathing mask , FiO2 100 percent 10 minute patient ventilate . Intolerance TMP / SMX define one following : Platelets &lt; 50000 platelets/mm3 absolute neutrophil count ( polys + band ) = &lt; 500 cells/mm3 least two occasion = &gt; 12 hour apart . Blistering rash , mucosal involvement , generalize maculopapular eruption intolerable pruritus . Transaminase &gt; 5 x ULN = &gt; 300 IU baseline abnormal . Daily temperature = &gt; 103 degree F begin 5th day treatment persist least 3 day responsive antipyretic therapy , discernible cause . Any severe lifethreatening adverse reaction TMP / SMX , investigator 's opinion , make continued recurrent treatment TMP / SMX inadvisable ( approved casebycase basis NIAID clinical monitor ) . Intolerance pentamidine define one following : Platelets &lt; 50000 platelets/mm3 absolute neutrophil count ( polys + band ) &lt; 550 cells/mm3 least two occasion = &gt; 12 hour apart . Serum creatinine &gt; 3.0 mg/dl . Systolic blood pressure &lt; 90 mm require supportive therapy . Symptomatic hypoglycemia blood glucose = &lt; 40 hyperglycemia require therapy . Pancreatitis laboratory confirmation ( abnormal amylase and/or lipase ) . Any severe lifethreatening adverse reaction pentamidine , investigator 's opinion , make continued recurrent treatment pentamidine inadvisable ( approved casebycase basis NIAID clinical monitor ) . Exclusion Criteria Coexisting Condition : Patients follow excluded : History Type I hypersensitivity ( i.e. , urticaria , angioedema , anaphylaxis ) , exfoliative dermatitis , lifethreatening reaction due trimetrexate . Patients less severe adverse reaction may enrol , opinion investigator , prohibit rechallenge drug . Concurrent Medication : Excluded : Myelosuppressive nephrotoxic agent . Other investigational drug include highdose steroid ( exceed physiologic replacement dos ) . Patients follow exclude : History Type I hypersensitivity ( i.e. , urticaria , angioedema , anaphylaxis ) , exfoliative dermatitis , lifethreatening reaction due trimetrexate . Patients less severe adverse reaction may enrol , opinion investigator , prohibit rechallenge drug .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Trimetrexate</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Injections , Intravenous</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Folic Acid Antagonists</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiprotozoal Agents</keyword>
</DOC>